Electronic Supplementary Material (ESI) for Green Chemistry. This journal is © The Royal Society of Chemistry 2017

Supplementary material

Marcin Drop^{,a} Xavier Bantreil,^b Katarzyna Grychowska,^a Gilbert Umuhire Mahoro,^b Evelina Colacino,^b Maciej Pawłowski,^a Jean Martinez,^{b,c} Gilles Subra,^c Pawel Zajdela and Frédéric Lamaty^{*b}

^a Department of Medicinal Chemistry, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland.

^b Institut des Biomolécules Max Mousseron (IBMM) UMR 5247, CNRS, Université de Montpellier, ENSCM, Université de Montpellier Campus Triolet Place Eugène Bataillon 34095 Montpellier cedex 5, France. E-mail: frederic.lamaty@umontpellier.fr

^c Institut des Biomolécules Max Mousseron (IBMM) UMR 5247, CNRS, Université de Montpellier, ENSCM, Bâtiment E, Faculté de Pharmacie 15, avenue Charles Flahault BP14491 34093 Montpellier cedex 5, France.

Table of contents

| General considerations | 2 |
|---|---|
| General procedure | 2 |
| Optimization of the reaction conditions | 4 |
| Description of compounds | 5 |
| HPLC chromatograms for the synthesis of 2e and 2f | 6 |
| NMR spectra of compounds 2a-g | 8 |
| References | |
| | |

General considerations

Organic transformations were carried out at ambient temperature, unless indicated otherwise. Organic solvents used in this study were of reagent grade and were used without purification. All other commercially available reagents were of the highest purity (from Sigma Aldrich, Alfa Aesar, Fluorochem, TCI). Metathesis catalysts used were either purchased from Sigma Aldrich, Apeiron-Synthesis (NO₂-Grela) or given by Umicore AG & Co. KG and Materia Inc. All workup and purification procedures were carried out with reagent-grade solvents under ambient atmosphere. Substrates **1a-g** were prepared according to literature.¹

Continuous flow experiments were performed using a Uniqsis Flowsyn Multi-X equipment connected to an automated fraction collector (Fig. 1). A 5 mL high temperature PTFE coil reactor was set-up. Flow rates were adapted to ensure an appropriate residence time in the reaction coil.



Figure 1. Flowsyn Multi-X equipment

HPLC analyses were performed with an Agilent model 1220 instrument at 214 nm using: column Phenomenex® Onyx Monolithic HD-C18, 2m, (50 x 4.6 mm), flow 3 ml/min, H₂O (0.1 % TFA)/CH₃CN (0.1 % TFA), gradient 0-0 % (30 s), 0-100 % (3 min) and 100 % (1 min).

¹H NMR and ¹³C NMR spectra were recorded at 400 MHz and 101 MHz (Bruker Avance III) or at 600 MHz and 150 MHz (Bruker Avance III) using CDCl₃, as solvent. Chemical shifts are given in ppm. The *J* values are reported in Hertz (Hz), and the splitting patterns are designated as follows: s (singlet), d (doublet), dd (doublet of doublet), t (triplet), m (multiplet), bs (broad singlet).

General procedure

Flow Procedure using one pump. The mixture of substrate (1 mmol), catalyst (0.03 mmol, 3 mol%) and dimethylcarbonate (8 mL, 0.125 mmol) was prepared in a vial. After setting the temperature to 120°C, the valve position was switched to place the mixture inline. The reaction mixture was then flowed into the 5mL PTFE residence coil and then through a back-pressure-regulator (BPR) rated to 6.9 bars (100 psi). The collected sample was quenched with ethylvinyl ether to stop the reaction before drying under reduced pressure. Then the residue was diluted with dichloromethane and filtrated through a layer of silica gel (about 1g). The filtrate was evaporated and the obtained residue was treated with diethyl ether giving a grey-white precipitate, which was filtrated off and dried under reduced pressure.

Flow Procedure using two pumps. A solution of substrate **1a** (430.5 mg, 1 mmol) in dimethylcarbonate (4 mL) was prepared and connected to pump A. Similarly, a solution of **M2** (28.5 mg, 0.03 mmol) in dimethyl carbonate (4 mL) was prepared and connected to pump B. After setting the temperature to 120°C, both valve positions were switched to place the mixture inline. Solution A and B, pumped using pump A and pump B, respectively, were flowed in a T-shaped mixer, then into the 5mL PTFE residence coil and then through a back-pressure-regulator (BPR) rated to 6.9 bars (100 psi) at a flow rate ensuring a 1 min residence time (5 mL.min⁻¹). The collected sample was quenched with ethylvinyl ether to stop the reaction before drying under reduced pressure. Then the residue was

diluted with dichloromethane and filtrated through a layer of silica gel (about 1g). The filtrate was evaporated and the obtained residue was treated with diethyl ether giving a grey-white precipitate, which was filtrated off and dried under reduced pressure. Pure compound (334.0 mg, 83% yield) was obtained as a grey-white solid.

Optimization of the reaction conditions

| NO2 NO2 + 1a Catalyst + Solvent Reservoir bottle | | | CO ₂ Me ² 1a rst nt bottle | Pump (flow rate) | Heating (residence V = 5 | g coil B time, T) mL | BPR ack Pressu Regulator (100 psi) | ure | Ts N CO ₂ 2a | pMe | | |
|--|--------|----------------------------|--|------------------------|--------------------------------|-----------------------------------|---|--------|----------------------------------|---------|--------|--|
| | | C) Residence Time (min) | | HPLC Conv. (%) | | | | | | | | |
| | T (°C) | | G-II | NO ₂ -Grela | HG-II | M51 | M5 ₂ | M | 12 | M20 | M31 | |
| | | | 3mol% | 3mol% | 3mol% | 3mol% | 3mol% | 2mol% | 3mol% | 3mol% | 3mol% | |
| | | 20 | | | | | | | 92 (0) | | | |
| | 90 | 30 | 72 (2) | 74 (2) | 94 (3) | 96 (<1) | 14 (0) | 84 (0) | 98 (0) | 94 (0) | 25 (0) | |
| | | 50 | | | | | | 84 (0) | 88 (0) | | | |
| | | 5 | 68 (3) | 70 (2) | | 85 (0) | 10 (0) | | 86 (<1) | 93 (0) | 25 (0) | |
| | 100 | 10 | | | | | | | 93 (<1) | 94 (0) | | |
| | | 20 | | | | | | | 95 (<1) | | | |
| | | 30 | | | | | | | 84 (<1) | | | |
| | 110 | 5 | | | | | | 85 (0) | 94 (0) | 89 (0) | | |
| | | 10 | | | | | | | 95 (0) | | | |
| | | 20 | | | | | | | 95 (0) | | | |
| | 90 | 30 | 75 (1) | 73 (2) | 95 (4) | 85 (0) | 22 (0) | | 23 (0) | 60 (<1) | 23 (0) | |
| | 100 | 30 | | | | | | | 51 (2) | | | |
| | | 60 | | | | | | | E 4 (4) | | | |

94 (4)

94 (5)

85 (4)

 $M2_2$

3mol%

35 (3)

88 (<1)

75 (<1)

77 (3)

53 (2)

96 (<1)

79 (3)

92 (1)

92(1)

74 (1)

75 (1)

98 (0)

92 (1)

98 (0)

97 (0)

84 (2)

98 (0)

97 (0)

96 (0)

96 (0)

50(1)

57 (1)

46 (2)

21 (0)

11 (0)

19 (0)

10(0)

7(0)

5 (0)

77 (2)

85(1)

82 (0)

73 (<1)

78 (0)

69(1)

Table S1. Optimization of the reaction conditions^a

Ts

ſ

60

30

30

50

10

20

30

1

5

10

1

5

30

1

5

10

74 (1)

76 (1)

71 (2)

84 (2)

85 (3)

73 (2)

Solvent

DCM

AcOEt

DMC

110

90

100

110

120

130

^a Reaction conditions: 1a (0.125 mmol), catalyst (3 mol%), solvent (1 mL), T, residence time. HPLC conversion of **1a** into **2a** is given. Ratio of isomer **iso-1a** is given in brackets.

Isomer iso-1a was isolated after 2.0 mmol scale RCM using HG-II (conditions from Table 1, entry 4 (DMC, 110°C, 5 min)) and fully characterized (see below).



Description of compounds

Methyl (Z)-2-(((4-methyl-*N*-(prop-1-en-1-yl)phenyl)sulfonamido)(2-nitrophenyl)methyl) acrylate (Iso-1a)

¹H NMR (600 MHz, CDCl₃) δ (ppm) 7.94 (dd, *J* = 8.1, 1.3 Hz, 1H), 7.77 (d, *J* = 7.6 Hz, 1H), 7.64 (td, *J* = 7.7, 1.2 Hz, 1H), 7.59 (d, *J* = 8.4 Hz, 2H), 7.47 (td, *J* = 7.2, 1.2 Hz, 1H), 7.23 (d, *J* = 7.8 Hz 2H), 6.97 (s, 1H), 6.47 (s, 1H), 6.02 (dd, *J* = 13.8, 1.6 Hz, 1H), 5.53 (d, *J* = 1.2 Hz, 1H), 5.45 (dq, *J* = 13.5, 6.7 Hz, 1H), 3.56 (s, 3H), 2.41 (s, 3H), 1.62 (dd, *J* = 6.7, 1.6 Hz, 3H).

¹³C NMR (150 MHz, CDCl₃) δ (ppm) 165.6, 148.1, 143.6, 137.8, 137.2, 134.2, 133.4, 131.0, 130.8, 129.4, 128.9, 127.9, 125.8, 125.4, 121.1, 58.9, 52.3, 21.7, 15.7.

HRMS calculated for $C_{21}H_{23}N_2O_6S$: 431.1277. Found: 431.1274.

Methyl 2,5-dihydro-2-(2-nitrophenyl)-1-tosyl-1H-pyrrole-3-carboxylate (2a)

White solid, 87% yield. ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.90 (d, *J* = 8.0 Hz, 1H), 7.80 (d, *J* = 8.2 Hz, 2H), 7.61 – 7.51 (m, 2H), 7.41 (ddd, *J* = 8.5, 5.3, 3.5 Hz, 1H), 7.34 (d, *J* = 8.0 Hz, 2H), 6.75 (dd, *J* = 4.0, 2.0 Hz, 1H), 6.73 – 6.65 (m, 1H), 4.61 (ddd, *J* = 17.4, 6.0, 2.0 Hz, 1H), 4.36 (dt, *J* = 17.4, 2.7 Hz, 1H), 3.53 (s, 3H), 2.43 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 161.7, 148.9, 144.3, 136.7, 135.8, 135.2, 133.5, 133.3, 130.2, 129.8, 128.7, 127.9, 124.7, 62.4, 55.8, 52.2, 21.7. Data in agreement with lit.²

Methyl 2-(2-chlorophenyl)-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate (2b)

White solid, 91% yield. ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.59 (d, J = 8.2 Hz, 2H), 7.31 – 7.27 (m, 1H), 7.25 – 7.11 (m, 5H), 6.81 – 6.79 (m, 1H), 6.17 – 6.12 (m, 1H), 4.59 – 4.42 (m, 2H), 3.57 (s, 3H), 2.39 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 162.1, 143.7, 137.3, 136.5, 134.9, 134.86, 133.8, 130.0, 129.9, 129.8, 129.2, 127.5, 127.0, 65.5, 55.6, 52.0, 21.6. Data in agreement with lit.³

Methyl 2-(2-methoxyphenyl)-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate (2c)

White solid, 88% yield.

¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.37 (d, *J* = 8.0 Hz, 2H), 7.23 – 7.17 (m, 2H), 7.11 (d, *J* = 8.0 Hz, 2H), 6.88 (td, *J* = 7.5, 0.9 Hz, 1H), 6.76 (dd, *J* = 4.0, 2.0 Hz, 1H), 6.68 – 6.64 (m, 1H), 6.00 (dt, *J* = 6.0, 1.9 Hz, 1H), 4.51 (dt, *J* = 16.5, 2.4 Hz, 1H), 4.37 (ddd, *J* = 16.5, 6.1, 1.9 Hz, 1H), 3.56 (s, 6H), 2.36 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 162.5, 157.6, 142.9, 136.2, 135.9, 134.3, 130.5, 129.4, 129.3, 127.2, 126.9, 120.6, 111.1, 65.1, 55.5, 55.4, 51.8, 21.6. Data in agreement with lit.¹

Methyl 2-phenyl-1-tosyl-2,5-dihydro-1H-pyrrole-3- carboxylate (2d)

White solid, 92% yield. ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.42 (d, *J* = 8.0 Hz, 2H), 7.25 – 7.18 (m, 5H), 7.14 (d, *J* = 8.0 Hz, 2H), 6.78 (dd, *J* = 3.8, 2.0 Hz, 1H), 5.74 (dt, *J* = 5.7, 2.0 Hz, 1H), 4.51 (dt, *J* = 17.1, 2.4 Hz, 1H), 4.38 (ddd, *J* = 17.1, 5.8, 1.9 Hz, 1H), 3.58 (s, 3H), 2.37 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 162.3, 143.4, 139.5, 135.8, 135.7, 129.6, 128.4, 128.2, 127.9, 127.2, 69.1, 55.0, 51.9, 21.6. Data in agreement with lit.⁴

Methyl 2-(3-methoxyphenyl)-1-tosyl-2,5-dihydro-1H-pyrrole-3-carboxylate (2e)

White solid, 52% yield. ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.42 (d, *J* = 7.6 Hz, 2H), 7.20 – 7.07 (m, 3H), 6.84 (d, *J* = 7.3 Hz, 1H), 6.77 (s, 2H), 6.67 (s, 1H), 5.71 (s, 1H), 4.51 (d, *J* = 16.9 Hz, 1H), 4.37 (dd, *J* = 16.9, 4.5 Hz, 1H), 3.71 (s, 3H), 3.59 (s, 3H), 2.36 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 162.3, 159.6, 143.4, 140.8, 135.9, 135.8, 129.5, 129.4, 127.2, 120.5, 113.7, 113.4, 69.0, 55.2, 55.1, 52.0, 21.6. Data in agreement with lit.¹

Methyl 2-(4-chlorophenyl)-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate (2f)

White solid, 68% yield. ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.45 (d, *J* = 8.1 Hz, 2H), 7.18 (q, *J* = 8.6 Hz, 6H), 6.78 (s, 1H), 5.68 (d, *J* = 5.3 Hz, 1H), 4.50 (d, *J* = 17.2 Hz, 1H), 4.39 (dd, *J* = 16.5, 5.0 Hz, 1H), 3.59 (s, 3H), 2.39 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 162.2, 143.8, 138.2, 136.1, 135.5, 135.4, 134.0, 129.7, 129.2, 128.6, 127.2, 68.4, 55.1, 52.0, 21.6. Data in agreement with lit.¹

Methyl 2-(4-methoxyphenyl)-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate (2g)

White solid, 81% yield. ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.43 (d, *J* = 8.2 Hz, 2H), 7.14 (t, *J* = 8.1 Hz, 4H), 6.76 (d, *J* = 8.5 Hz, 3H), 5.70 (d, *J* = 5.5 Hz, 1H), 4.48 (dt, *J* = 17.0, 2.3 Hz, 1H), 4.35 (ddd, *J* = 17.1, 5.7, 1.8 Hz, 1H), 3.77 (s, 3H), 3.59 (s, 3H), 2.37 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 162.4, 159.5, 143.3, 135.8, 135.5, 131.7, 129.6, 129.0, 127.2, 113.8, 68.6, 55.4, 54.9, 51.9, 21.6. Data in agreement with lit.¹

HPLC chromatograms for the synthesis of 2e and 2f

Since compounds **2e** and **2f** could not be isolated in high yields, HPLC chromatograms recorded after the reaction are provided to demonstrate that conversion was almost complete in both cases, with no degradation nor side-products.



Description: Injection volume:

Instrument: Injection date: Acq. method:

Agilent1220 5/25/2016 5:56:25 PM 0a100_3min_214nm.M

5.000



Signal:

VWD1 A, Wavelength=214 nm

| RT [min] | Area | Height | Peak Area Percent | | |
|----------|------------|------------|-------------------|--|--|
| 2.926 | 2913.62500 | 1186.59692 | 92.46 | | |
| 3.160 | 237.46588 | 98.04047 | 7.54 | | |

NMR spectra of compounds iso-1a and 2a-g

¹H NMR of Methyl (*E*)-2-(((4-methyl-*N*-(prop-1-en-1-yl)phenyl)sulfonamido)(2-nitrophenyl)methyl) acrylate **iso-1a**



¹³C NMR of Methyl (*E*)-2-(((4-methyl-*N*-(prop-1-en-1-yl)phenyl)sulfonamido)(2-nitrophenyl)methyl) acrylate **iso-1a**





^1H NMR of Methyl 2,5-dihydro-2-(2-nitrophenyl)-1-tosyl-1H-pyrrole-3-carboxylate 2a

¹³C NMR of Methyl 2,5-dihydro-2-(2-nitrophenyl)-1-tosyl-1*H*-pyrrole-3-carboxylate **2a**





¹H NMR of Methyl 2-(2-chlorophenyl)-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate **2b**

¹³C NMR of Methyl 2-(2-chlorophenyl)-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate **2b**



¹H NMR of Methyl 2-(2-methoxyphenyl)-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate **2c**



¹³C NMR of Methyl 2-(2-methoxyphenyl)-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate **2c**





¹³C NMR of Methyl 2-phenyl-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate **2d**



10 0 ppm 200

¹H NMR of Methyl 2-phenyl-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate **2d**

¹H NMR of Methyl 2-(3-methoxyphenyl)-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate **2e**



¹³C NMR of Methyl 2-(2-methoxyphenyl)-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate **2e**



¹H NMR of Methyl 2-(4-chlorophenyl)-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate **2f**



¹³C NMR of Methyl 2-(4-chlorophenyl)-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate **2f**





¹³C NMR of Methyl 2-(4-methoxyphenyl)-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate **2g**



¹H NMR of Methyl 2-(4-methoxyphenyl)-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate **2g**

References

1. K. Grychowska, B. Kubica, M. Drop, E. Colacino, X. Bantreil, M. Pawłowski, J. Martinez, G. Subra, P. Zajdel and F. Lamaty, *Tetrahedron*, 2016, **72**, 7462.

2. (a) H. Benakki, E. Colacino, C. Andre, F. Guenoun, J. Martinez and F. Lamaty, *Tetrahedron*, 2008, **64**, 5949; (b) P. Zajdel, K. Grychowska, F. Lamaty, E. Colacino, X. Bantreil, J. Martinez, M. Pawlowski, G. Satala, A. J. Bojarski, A. Partyka, A. Wesolowska, T. Kos, P. Popik and G. Subra, WO2015012704A1, 29 January, 2015; (c) K. Grychowska, G. Satala, T. Kos, A. Partyka, E. Colacino, S. Chaumont-Dubel, X. Bantreil, A. Wesolowska, M. Pawlowski, J. Martinez, P. Marin, G. Subra, A. J. Bojarski, F. Lamaty, P. Popik and P. Zajdel, *ACS Chem. Neurosci.*, 2016, **7**, 972.

3. W. Sun, X. Ma, L. Hong and R. Wang, *J. Org. Chem.*, 2011, **76**, 7826.

4. D. J. Aldous, A. S. Batsanov, D. S. Yufit, A. J. Dalencon, W. M. Dutton and P. G. Steel, *Org. Biomol. Chem.*, 2006, **4**, 2912.